dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-09 and is reviewed periodically as new material appears.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
=== Resistance === Bacteria that show no clinically relevant response to ertapenem include methicillin-resistant Staphylococcus species (including MRSA) as well as Acinetobacter, Aeromonas, Enterococcus, and Pseudomonas. Microorganisms can become resistant to ertapenem by producing carbapenemases, enzymes that inactivate the drug by opening the beta-lactam ring. Other mechanisms of resistance against carbapenems are development of efflux pumps that transport the antibiotics out of the bacterial cells, mutations of PBPs, and mutations of Gram-negative bacteria's porins which are necessary for carbapenems to enter the bacteria.
"It is so true that Bolívar has tried to persecute every able-bodied Peruvian without cause, and that when Brigadier General La Fuente was responsible for the last transformation of Trujillo [the Riva-Agüero prison] and that it was titled That Pacifier of the North, [Bolívar] instantly tried to overthrow him. La Fuente made the Peruvian cuirassiers hold on and punish the hussars of Bolívar's guard, who wanted to run over them" He was also accused of being very cruel against the troops of the Royal Army of Peru, where the repression was fierce, with executions of those who did not pay tithes, harassment of women, execution of prisoners without trial, slaughter of cattle, desecration of churches, imprisonment of women and children in Huanta and the burning of the towns of Iquicha, Caruahuran and Huayllas (absent violence on the royalist side). The guerrillas had to take refuge in the hills in the Republic of Iquicha. After independence, the royalist Indians of Huanta had to bear the punishment for supporting the monarchists: it was the payment of a tax of 50,000 pesos that the entire homonymous party had to collect (except the towns of Quinua, Guaychán and Acosvinchos), which demanded Marshal Antonio José de Sucre "for having rebelled against the system of Independence and freedom." In said imposition, coca prices were altered and caused an economic crisis. If the Iquicha Indians rose up against Bolívar's republic, it was neither because they were "deceived" nor because they wanted to perpetuate the most oppressive features of the colonial system. Quite the opposite.
=== Cleft === The Scar Free Foundation initiated the Cleft Collective, a large-scale multigenerational cohort study investigating the causes, treatments, and long-term outcomes of children born with cleft lip and/or palate. With over 10,000 participants recruited from all 16 Cleft Centres in the UK, the project stands as the largest biobank of its kind globally. The collected data is available for researchers from various disciplines, resulting in numerous peer-reviewed publications.
=== Further reading === Ball, S. J. The Cold War: An International History, 1947–1991 (1998). British perspective Beschloss, Michael, and Strobe Talbott. At the Highest Levels:The Inside Story of the End of the Cold War (1993) Braithwaite, Rodric et al. "Could the Soviet Union Have Survived? We ask four historians whether the demise of one of the 20th century's superpowers was as inevitable as it now seems." History Today (Oct 2020) 70#10 pp 8–10 [online]. Brooks, Stephen G., and William C. Wohlforth. "Power, globalization, and the end of the Cold War: Reevaluating a landmark case for ideas." International Security 25.3 (2001): 5-53. [online] Engel, Jeffrey A. When the World Seemed New: George H. W. Bush and the End of the Cold War (2017) Gaddis, John Lewis. The United States and the End of the Cold War: Implications, Reconsiderations, Provocations (1992) online Garthoff, Raymond. The Great Transition: American-Soviet Relations and the End of the Cold War (1994) online Goertz, Gary and Jack S. Levy, eds. Causal explanations, necessary conditions, and case studies: World War I and the End of the Cold War (2005), 10 essays from political scientists; online Hogan, Michael, ed. The End of the Cold War. Its Meaning and Implications (1992) articles from Diplomatic History Kalinovsky, Artemy M. "New Histories of the End of the Cold War and the Late Twentieth Century." Contemporary European History 27.1 (2018): 149–161. online Kegley Jr, Charles W. "How did the Cold War die? Principles for an autopsy." Mershon International Studies Review 38.Supplement_1 (1994): 11–41.
Sources: en.wikipedia.org
==== Phosphorylated chitosan ==== Water-soluble phosphorylated chitosan can be obtained by the reaction of phosphorus pentoxide and chitosan under low-temperature conditions using methane sulfonic acid as the catalyst; phosphorylated chitosan with good antibacterial activity and ionic properties can be prepared by graft copolymerization of chitosan monophosphate. The good water solubility and metal chelating properties of phosphorylated chitosan and its derivatives make them widely used in tissue engineering, drug delivery carriers, tissue regeneration, and the food industry. In tissue engineering, phosphorylated chitosan exhibits improved swelling and ionic conductivity. Although its crystallinity is reduced, its tensile strength remains largely unchanged. These properties make it useful for creating scaffolds that can support bone tissue regeneration by binding growth factors and promoting stem cell differentiation into bone-forming cells. Additionally, to enhance the solubility of chitosan-based hydrogels at neutral or alkaline pH, the derivative N-methylene phosphonic acid chitosan (NMPC-GLU) has been developed. This material maintains good mechanical strength and improve cell proliferation, making it valuable for biomedical applications.
The world's agrifood systems comprise a gargantuan global enterprise that each year produces approximately 11 billion tonnes of food and a multitude of non-food products, including 32 million tonnes of natural fibres and 4 billion m3 of wood. The estimated gross value of agricultural output in 2018 was US$3.5 trillion. Agrifood systems employment represented 39.1% of global employment in 2022, down from 52.2% in 2000. In 2021 primary production alone provides about one-quarter of all employment globally, more than half in sub-Saharan Africa and almost 60 percent in low-income countries. Including middle and downstream segments – from food storage and processing to transportation, retailing and consumption – agrifood systems are the backbone of many economies. Even in the European Union, the food and beverage industry employs more people than any other manufacturing sector.FAO approximates that 1.23 billion people are employed globally in agrifood systems, amounting to about one-third of the global labor force.
Wild birds impact many human activities, while domesticated birds are important sources of eggs, meat, feathers, and other products. Applied and economic ornithology aim to reduce the ill effects of problem birds and enhance gains from beneficial species.
Sources: en.wikipedia.org
=== High-throughput screening === Approved drugs are never identified as hits in high-throughput screens because the chemical libraries used in screening have not been optimized against any targets. However, methods like affinity chromatography and affinity selection-mass spectrometry are workhorses of the pharmaceutical industry, and AS-MS particularly has been documented to produce a significant number of hits across many classes of difficult-to-drug proteins. This is due in large part to the sheer volume of ligands that can be screened in a single assay. Researchers at the iHuman Institute at ShanghaiTech University employed of scheme in which 20,000 compounds per pool were screened against A2AR, a difficult G-protein coupled receptor to drug, with a 0.12% hit rate, leading to several high affinity ligands.
== History == Beginning in 2007, the British Engineering and Physical Sciences Research Council has funded development of ribosome-like molecular assemblers. Clearly, molecular assemblers are possible in this limited sense. A technology roadmap project, led by the Battelle Memorial Institute and hosted by several U.S. National Laboratories has explored a range of atomically precise fabrication technologies, including both early-generation and longer-term prospects for programmable molecular assembly; the report was released in December, 2007. In 2008, the Engineering and Physical Sciences Research Council provided funding of £1.5 million over six years (£1,942,235.57, $2,693,808.00 in 2021) for research working towards mechanized mechanosynthesis, in partnership with the Institute for Molecular Manufacturing, amongst others. Likewise, the term "molecular assembler" has been used in science fiction and popular culture to refer to a wide range of fantastic atom-manipulating nanomachines. Much of the controversy regarding "molecular assemblers" results from the confusion in the use of the name for both technical concepts and popular fantasies. In 1992, Drexler introduced the related but better-understood term "molecular manufacturing", which he defined as the programmed "chemical synthesis of complex structures by mechanically positioning reactive molecules, not by manipulating individual atoms". This article mostly discusses "molecular assemblers" in the popular sense.
=== Clothing and cosmetics === In July 2012, Collins launched her debut plus-size clothing collection online, ranging from sizes 16 to 22. Collins drew on her own experiences of struggling to find flattering and fashionable clothing in larger sizes and said she was "so happy to be able to offer bigger girls a clothing range that they can show their curves off in." In December 2012, Collins attended the Clothes Show Live at the National Exhibition Centre in Birmingham where she had her own stall featuring pieces from her collection that consumers could purchase. She returned to the exhibition the following year and won the award for "Best Designer" at the British Plus Size Awards in 2013. She also teamed up with fashion brand Simply Be to launch her own collection which included a range of bright prints, dresses and jackets, and opened the branches of the store at Highcross Leicester and MetroCentre in Gateshead, cutting the ribbon at the respective launch parties. A year later, Collins opened her own clothing boutique in Brentwood, Essex. She subsequently moved the Gemma Collins Boutique to a different area of Brentwood in November 2014, before returning to the previous location, albeit in a different building, in June 2017. In April 2015, Collins launched her fashion range with women's clothing retailer Evans. In November 2017, Collins collaborated with fashion website Boohoo.com to release a clothing range aimed at plus-sized women. The following year, she went on to release a collection of swimwear with the retailer.
Alprazolam is a GABAA receptor positive allosteric modulator. When it binds to the receptor, effects of GABA are enhanced, leading to inhibition of neurons in the brain. This results in effects including reduced anxiety, muscle relaxant, and anticonvulsant activity. The activity of alprazolam in the central nervous system is dose-dependent.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.